Novaliq announces first patient randomized in its ESSENCE phase 2b/3 trial of CyclASol® for the treatment of the signs and symptoms of dry eye disease

Heidelberg, Germany – November 9, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its ESSENCE Phase 2b/3 clinical trial that will evaluate CyclASol® for the treatment of the signs…